Carbamazepine is the first line treatment for patients affected by KCNQ2 developmental and epileptic encephalopathy. It is efficient to reduce or stop seizures in this context. However, its effect on… Click to show full abstract
Carbamazepine is the first line treatment for patients affected by KCNQ2 developmental and epileptic encephalopathy. It is efficient to reduce or stop seizures in this context. However, its effect on the neurodevelopmental outcomes is debated. The aim of this study was to evaluate the efficacy of long‐term oral administration of carbamazepine in a mouse model of Kcnq2 dysfunction.
Keywords:
epileptic encephalopathy;
carbamazepine;
kcnq2 developmental;
developmental epileptic;
long term;
mouse model
Journal Title: Epilepsia Open
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Epilepsia Open
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!